NEUROPACE, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.74 USD | -3.01% |
|
-8.70% | -24.64% |
| May. 13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
| May. 08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| NEUROPACE, INC. | Other Advanced Medical Equipment & Technology | -3.38% | -8.70% | -24.64% | +66.74% | - | 230M |  | |  |
Technical Rankings Surperformance
- Stock Market
- Equities
- NPCE Stock
- Charts NeuroPace, Inc.
- Comparison Chart